In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of ...In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market. The article delves into the intricacies of implementing a fast-to-clinic/market strategy, underlining the empowering role of strategic decision-making in preclinical and commercial stages. The plan advocates for a phase-appropriate approach, where the development decision is tailored to each phase of the product’s lifecycle. This ensures that resources are allocated efficiently, risks are managed effectively, and the product can move through the development pipeline accelerated without compromising quality or regulatory compliance. The article also discusses the role of CDMOs in facilitating rapid product development and the essential factors biotech companies must consider when selecting a partner for outsourcing. These factors include the CDMO’s expertise in navigating regulatory landscapes, technological capabilities, and ability to scale processes efficiently. Moreover, the article stresses the importance of agility and flexibility in the fast-to-clinic/market approach. Biotech companies are encouraged to adopt adaptable strategies that respond to the fast-evolving regulatory and market landscapes.展开更多
China is the leading importer of soybeans in the world. If China adopts high yield biotech soybean varieties, China＇s soybean production would increase significantly and this would impact global soybean markets. This...China is the leading importer of soybeans in the world. If China adopts high yield biotech soybean varieties, China＇s soybean production would increase significantly and this would impact global soybean markets. This paper assesses the possible effects of adoption of herbicide-tolerant, biotech soybeans in China and its impact on the world soybean trade. Results indicate that under a low technology fee and high adoption rate, China would be able to satisfy its soybean food demand. Urban consumers＇ strong preference for non-biotech soybean oil may lead to increase in imports of non-biotech soybeans.展开更多
Modern biotechnology booms in the molecular life science. It brings about a promising future for improving human health, foodstuff, environment and energy and is of significance to improve traditional agriculture, dru...Modern biotechnology booms in the molecular life science. It brings about a promising future for improving human health, foodstuff, environment and energy and is of significance to improve traditional agriculture, druamakins and other展开更多
文摘In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market. The article delves into the intricacies of implementing a fast-to-clinic/market strategy, underlining the empowering role of strategic decision-making in preclinical and commercial stages. The plan advocates for a phase-appropriate approach, where the development decision is tailored to each phase of the product’s lifecycle. This ensures that resources are allocated efficiently, risks are managed effectively, and the product can move through the development pipeline accelerated without compromising quality or regulatory compliance. The article also discusses the role of CDMOs in facilitating rapid product development and the essential factors biotech companies must consider when selecting a partner for outsourcing. These factors include the CDMO’s expertise in navigating regulatory landscapes, technological capabilities, and ability to scale processes efficiently. Moreover, the article stresses the importance of agility and flexibility in the fast-to-clinic/market approach. Biotech companies are encouraged to adopt adaptable strategies that respond to the fast-evolving regulatory and market landscapes.
文摘China is the leading importer of soybeans in the world. If China adopts high yield biotech soybean varieties, China＇s soybean production would increase significantly and this would impact global soybean markets. This paper assesses the possible effects of adoption of herbicide-tolerant, biotech soybeans in China and its impact on the world soybean trade. Results indicate that under a low technology fee and high adoption rate, China would be able to satisfy its soybean food demand. Urban consumers＇ strong preference for non-biotech soybean oil may lead to increase in imports of non-biotech soybeans.
文摘Modern biotechnology booms in the molecular life science. It brings about a promising future for improving human health, foodstuff, environment and energy and is of significance to improve traditional agriculture, druamakins and other
